<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117985</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2016-05</org_study_id>
    <nct_id>NCT03117985</nct_id>
  </id_info>
  <brief_title>Tracking and Exploring the Source of Viral REbound</brief_title>
  <acronym>TESOVIR</acronym>
  <official_title>Tracking and Exploring the Source of Viral REbound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire de Virologie Moléculaire de Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phylogenic analysis of viruses hosted in marker positive reservoir cells including CD32a+ CD4
      T lymphocytes and rebounding viruses after treatment interruption
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 1</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 2</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 3</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 4</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 5</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 6</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 8</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 10</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic Cartography</measure>
    <time_frame>Week 12</time_frame>
    <description>Measuring the genetic distance between viruses contained in marker positive reservoir cells including CD32a+ CD4 T (T4cells) lymphocytes and viruses rebounding after treatment interruption. This cartography will be made when Plasma Human Immunodeficiency Virus -1 ribonucleic acid (RNA) superior or equal to 1000 copies/ml</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>Antiretroviral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stopping antiretroviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no drug</intervention_name>
    <description>Stopping antiretroviral therapy</description>
    <arm_group_label>Antiretroviral therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age&gt;18year old

          -  Nadir CD4&gt;200/mm3

          -  CD4/CD8 ratio&gt; 0.5

          -  Continuous antiretroviral therapy for more than 2 years

          -  Plasma Human Immunodeficiency Virus (HIV) 1 Ribonucleic acid (RNA) &lt;50 copies/ml in
             the last 2 years

          -  Viral Load (VL)&lt;20copies at inclusion

          -  Patients who are willing to participate and who understand the trial (particularly,
             the obligation to have protected intercourse during the study).

          -  Informed consent

          -  Short half-life treatment

          -  Health insurance

          -  A subset of CD4 (T4cells) express CD32a.

        Exclusion Criteria:

          -  - Acquired Immune Deficiency Syndom (AIDS)

          -  Pregnancy

          -  Human immunodeficiency virus (HIV)-2 co infection

          -  Thrombopenia

          -  Neurological events during primary infection

          -  Hepatitis B + (HBV+)

          -  Hepatitis C + (HCV+)

          -  Cancer during the last 5 years.

          -  Life expectancy &lt; 12 months

          -  Autoimmunity

          -  Acute infectious disease in the last 60 days.

          -  Hemoglobin&lt;7g/dl

          -  Glomerular filtration &lt; 60ml/min

          -  Refusing protected intercourse

          -  Risk of HIV transmission

          -  Psychiatric disorders.

          -  Alcool and drug abuse

          -  Involvement in another clinical trial evaluating a therapeutic.

          -  Being under tutorship

          -  Being deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT HOCQUELOUX</last_name>
    <role>Study Director</role>
    <affiliation>CHR ORLEANS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DESPUJOLS Aurélie</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chr Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HOCQUELOUX Laurent, MD</last_name>
      <email>laurent.hocqueloux@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>HOCQUELOUX Laurent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PRAZUCK Thierry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Descours B, Petitjean G, López-Zaragoza JL, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, Lelievre JD, Benkirane M. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature. 2017 Mar 23;543(7646):564-567. doi: 10.1038/nature21710. Epub 2017 Mar 15. Erratum in: Nature. 2017 Jun 28;546(7660):686.</citation>
    <PMID>28297712</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV reservoirs</keyword>
  <keyword>HIV persistence</keyword>
  <keyword>Viral rebound</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

